OVID · Ovid Therapeutics Inc
United States · RS rating 65 · As of 2026-11-03
| Price | 2.40 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 65 / 65 / 49 / 91 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 42 / 31 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +135.3% |
| Sales growth Q/Q | +443.9% |
| Distance from 52-week high | +18.9% |
| Market cap (USD) | $463.7M |